NATCO Pharma Management

Management Kriterienprüfungen 1/4

NATCO Pharma CEO ist Rajeev Nannapaneni , ernannt in Jun 2012, hat eine Amtszeit von 12.42 Jahren. besitzt direkt 0.63% der Aktien des Unternehmens, im Wert von ₹1.61B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.8 Jahre bzw. 2.3 Jahre.

Wichtige Informationen

Rajeev Nannapaneni

Geschäftsführender

₹98.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	12.4yrs
Eigentum des Geschäftsführers	0.6%
Durchschnittliche Amtszeit des Managements	7.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.3yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Rajeev Nannapaneni (47 yo)

12.4yrs

Amtszeit

₹98,670,000

Vergütung

Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Venkaiah Nannapaneni	MD & Chairman	43.2yrs	₹100.77m	25.1% ₹ 64.2b
Rajeev Nannapaneni	CEO & Vice Chairman	12.4yrs	₹98.67m	0.63% ₹ 1.6b
S. V. V. Appa Rao	Chief Financial Officer	8.8yrs	₹13.36m	keine Daten
Donthineni Rao	President of Technical Affairs & Whole Time Director	no data	₹33.69m	0.030% ₹ 77.3m
Chekuri Ramesh	Company Secretary & Compliance Officer	2.6yrs	₹2.61m	keine Daten
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	no data	₹20.16m	0.023% ₹ 58.7m
Pavan Bhat	Executive VP of Technical Operations & Director	7.8yrs	₹32.12m	0.013% ₹ 33.2m
Nadella Rao	VP & Head of Operations	no data	keine Daten	keine Daten
N. Rao	Executive Vice President of Corporate Affairs	no data	keine Daten	keine Daten
James Rajakumar	Vice President of Marketing & Sales - Domestic	less than a year	keine Daten	keine Daten
A. Lakshminarayana	Senior Vice President of HR & Organisational Development	no data	keine Daten	0.0062% ₹ 15.8m
M. Reddy	Executive Vice President of R&D	30.6yrs	keine Daten	0.025% ₹ 62.9m

7.8yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrenes Management: 524816Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Venkaiah Nannapaneni	MD & Chairman	43.2yrs	₹100.77m	25.1% ₹ 64.2b
Rajeev Nannapaneni	CEO & Vice Chairman	19yrs	₹98.67m	0.63% ₹ 1.6b
Donthineni Rao	President of Technical Affairs & Whole Time Director	9.8yrs	₹33.69m	0.030% ₹ 77.3m
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	10yrs	₹20.16m	0.023% ₹ 58.7m
Pavan Bhat	Executive VP of Technical Operations & Director	2.3yrs	₹32.12m	0.013% ₹ 33.2m
Madireddi Naidu	Independent Director	9.8yrs	₹330.00k	keine Daten
Agnihotra Dakshina Chavali	Independent Director	less than a year	keine Daten	keine Daten
Dronadula Bhaskar	Independent Director	less than a year	keine Daten	keine Daten
Lakshminarayana Bolisetty	Independent Non-Executive Director	less than a year	keine Daten	keine Daten
Kantipudi Suma	Independent Non-Executive Director	less than a year	keine Daten	keine Daten
Nitin Jain	Independent Non-Executive Director	less than a year	keine Daten	keine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: 524816Die Vorstandsmitglieder gelten nicht als erfahren ( 2.3 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

NATCO Pharma Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Insider recently sold ₹30m worth of stock

High number of new directors

Less than half of directors are independent

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

Recent updates

NATCO Pharma Limited to Report First Half, 2025 Results on Nov 12, 2024

Insider recently sold ₹30m worth of stock

High number of new directors

Natco Pharma Limited Submits Abbreviated New Drug Application Containing A Paragraph IV Certification with the U.S. Food and Drug Administration

Less than half of directors are independent

Price target increased by 14% to ₹1,209

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024

Dividend of ₹3.00 announced

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

Board Member recently sold ₹6.0m worth of stock

Investor sentiment improves as stock rises 21%

Price target increased by 9.1% to ₹1,064

Full year 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024

Now 22% undervalued

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹1.25 per share

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Insider recently bought ₹161k worth of stock

NATCO Pharma Limited Files Generic Olaparib Tablets in USA

Upcoming dividend of ₹1.25 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023

NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023

MD & Director recently bought ₹5.0m worth of stock

Natco Pharma Limited Announces Double Bench of the High Court of Delhi Dismiss an Appeal Filed by FMC Corporation, FMC Singapore and FMC India

Price target decreased to ₹709

Upcoming dividend of ₹0.75 per share

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2022-23, Payable from 30 November 2022

NATCO Pharma Limited to Report Q2, 2023 Results on Nov 10, 2022

Natco Pharma Limited Announces FMC Corporation and FMC Singapore Serve A Copy of Appeal on Natco

Natco Pharma Limited Launches Chlorantraniliprole

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2022

NATCO Announces Tentative Approval to Its ANDA for Trabectedin (Generic for Yondelis®)

Upcoming dividend of ₹3.50 per share

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on August 30, 2022

NATCO Pharma Limited to Report Q1, 2023 Results on Aug 09, 2022

NATCO Pharma Limited Announces the Launch of the First Generic Version of Nexavar® (Sorafenib) Tablets in 200 Mg Strength in the U.S. Market

Price target decreased to ₹894

Full year 2022 earnings: EPS and revenues miss analyst expectations

FMC Corporation Files a Suit against NATCO Pharma Limited

NATCO Pharma Limited to Report Q4, 2022 Results on May 30, 2022